Msdc 0160 Buy Apr 2026

MSDC-0160 is a novel, clinical-stage drug candidate originally developed for . It is the prototype of a new class of insulin sensitizers called mTOT Modulators (Mitochondrial Target of Thiazolidinediones). Unlike first-generation insulin sensitizers like pioglitazone, MSDC-0160 is PPAR

It may prevent or reverse dyskinesia (involuntary movements) caused by standard Parkinson's medications. 2. Alzheimer’s Disease (AD) MSDC-0160 - Metabolic Solutions Development Company msdc 0160 buy

By modulating mitochondrial metabolism, it prevents the over-activation of mTOR , a key nutrient sensor that, when overactive, is linked to neurodegeneration and inflammation. 🧠 Therapeutic Applications It blocks the entry of pyruvate into the

This forced "metabolic shift" encourages cells to use alternative fuel sources like ketones and fatty acids through -oxidation. it prevents the over-activation of mTOR

It blocks the entry of pyruvate into the mitochondria, the main gateway for carbohydrate metabolism.

Research has expanded beyond diabetes to several age-related and neurodegenerative conditions: 1. Parkinson’s Disease (PD)